Trials that use: Multiplicity adjustment
New to this method? Read the tutorial →
10,417 results
- SMS TurkeyIndependent statistical analysis of SMS Turkey: Harnessing the Power of Text Messaging to Promote Smoking Cessation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- SMV + SOF With/Without RBV for IFN-II Patients With CHC: Complete Statistical AnalysisIndependent statistical analysis of SMV + SOF With/Without RBV for IFN-II Patients With CHC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02214420).
- SNIFFLE-3Independent statistical analysis of Efficacy & Safety of Nasal Influenza Immunisation in Children: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02549365).
- SOCIALIndependent statistical analysis of Supporting Our Caregivers In ADRD Learning (SOCIAL): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06276023).
- Socially Assistive Robots for Interaction With Older Adults With Dementia: Complete Statistical AnalysisIndependent statistical analysis of Socially Assistive Robots for Interaction With Older Adults With Dementia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04384978).
- SOCRIndependent statistical analysis of Sensor Optimization of Cardiac Resynchronization Therapy Response: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01832493).
- SOCRATESIndependent statistical analysis of [SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES]: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Sodium Chloride and Protein-Bound Toxin Removal in Hemodiafiltration: Complete Statistical AnalysisIndependent statistical analysis of Sodium Chloride and Protein-Bound Toxin Removal in Hemodiafiltration: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01923961).
- Sodium Fluorescein-Guided Resection of Pediatric Neurosurgical Tumors: Complete Statistical AnalysisIndependent statistical analysis of Sodium Fluorescein-Guided Resection of Pediatric Neurosurgical Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03752203).
- Sodium Nitroprusside in Early Course Schizophrenia: Complete Statistical AnalysisIndependent statistical analysis of Sodium Nitroprusside in Early Course Schizophrenia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04986072).
- Sodium Pyruvate Nasal Spray Treatment of COVID-19 Infection: Complete Statistical AnalysisIndependent statistical analysis of Sodium Pyruvate Nasal Spray Treatment of COVID-19 Infection: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04824365).
- Sodium Risedronate Tablets – Special Drug Use Surveillance in Patients With Osseous Paget’s Disease (All-case Surveillance) -48-week Surveillance -: Complete Statistical AnalysisIndependent statistical analysis of Sodium Risedronate Tablets - Special Drug Use Surveillance in Patients With Osseous Paget's Disease (All-case Surveillance) -48-week Surveillance -: primary endpoint results, effect estimate with confidence interval, sample-size…
- Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy: Complete Statistical AnalysisIndependent statistical analysis of Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy: primary endpoint results, effect…
- SOF/VEL ESRDIndependent statistical analysis of Sofosbuvir/Velpatasvir in Adults With Chronic Hepatitis C Virus Infection Who Are on Dialysis for End Stage Renal Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation: Complete Statistical AnalysisIndependent statistical analysis of Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Sofosbuvir and Ribavirin in Treatment-Naive and Treatment-Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection: Complete Statistical AnalysisIndependent statistical analysis of Sofosbuvir and Ribavirin in Treatment-Naive and Treatment-Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Sofosbuvir Plus Ribavirin Administered for Either 12 or 24 Weeks in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) Infection: Complete Statistical AnalysisIndependent statistical analysis of Sofosbuvir Plus Ribavirin Administered for Either 12 or 24 Weeks in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) Infection: primary endpoint results,…
- SOFTIndependent statistical analysis of Bladder Drainage During Labor: A Randomized Controlled Study of Obstetric Foley Therapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- SOLARIndependent statistical analysis of Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- SOLEOIndependent statistical analysis of A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive Disorder: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- SOLO3Independent statistical analysis of Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received…
- SOM230Independent statistical analysis of Pasireotide LAR in Severe Polycystic Liver Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01670110).
- Somatosensory Profiling in Radicular Pain Patients And it’s Correlation With Treatment Outcome: Complete Statistical AnalysisIndependent statistical analysis of Somatosensory Profiling in Radicular Pain Patients And it's Correlation With Treatment Outcome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- SOMNOSIndependent statistical analysis of Effects of Continuous Positive Airway Pressure (CPAP) on Glucose Metabolism: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01503164).
- Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Sonothrombolysis in Patients With STEMI: Complete Statistical AnalysisIndependent statistical analysis of Sonothrombolysis in Patients With STEMI: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03092089).
- SonoVue®-Enhanced Ultrasound (US) Versus Unenhanced US for Focal Liver Lesion Characterization: Complete Statistical AnalysisIndependent statistical analysis of SonoVue®-Enhanced Ultrasound (US) Versus Unenhanced US for Focal Liver Lesion Characterization: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- SonoVue®-Enhanced Ultrasound Versus Unenhanced US for Focal Liver Lesion Characterization: Complete Statistical AnalysisIndependent statistical analysis of SonoVue®-Enhanced Ultrasound Versus Unenhanced US for Focal Liver Lesion Characterization: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00788697).
- SOPRAIndependent statistical analysis of Selinexor (KPT-330) in Older Patients With Relapsed AML: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02088541).
- Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer: Complete Statistical AnalysisIndependent statistical analysis of Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Sorafenib for the Treatment of Chronic Lymphocytic Leukemia (CLL): Complete Statistical AnalysisIndependent statistical analysis of Sorafenib for the Treatment of Chronic Lymphocytic Leukemia (CLL): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01510756).
- Sorafenib in Children and Young Adults With Recurrent or Progressive Low-Grade Astrocytomas: Complete Statistical AnalysisIndependent statistical analysis of Sorafenib in Children and Young Adults With Recurrent or Progressive Low-Grade Astrocytomas: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Sorafenib in Treating Patients Who Are Undergoing Surgery for Metastatic Kidney Cancer: Complete Statistical AnalysisIndependent statistical analysis of Sorafenib in Treating Patients Who Are Undergoing Surgery for Metastatic Kidney Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer: Complete Statistical AnalysisIndependent statistical analysis of Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00126568).
- Sorafenib in Treating Patients With Metastatic or Unresectable Kidney Cancer: Complete Statistical AnalysisIndependent statistical analysis of Sorafenib in Treating Patients With Metastatic or Unresectable Kidney Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00496756).
- Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer: Complete Statistical AnalysisIndependent statistical analysis of Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03037437).
- Sorafenib Tosylate and Gene Expression Analysis in Patients Undergoing Surgery For High-Risk Localized Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Sorafenib Tosylate and Gene Expression Analysis in Patients Undergoing Surgery For High-Risk Localized Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer: Complete Statistical AnalysisIndependent statistical analysis of Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors: Complete Statistical AnalysisIndependent statistical analysis of Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00131911).
- Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin’s Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00131937).
- Sorafenib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Sorafenib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer: Complete Statistical AnalysisIndependent statistical analysis of Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Soy Protein/Effexor Hormone Therapy for Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Soy Protein/Effexor Hormone Therapy for Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00354432).
- SPAFIndependent statistical analysis of Apixaban Drug Utilization Study In Stroke Prevention In Atrial Fibrillation (Spaf): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- SPARCIndependent statistical analysis of Immediate Prostatectomy vs. Cabozantinib Followed by Prostatectomy in Men With High-Risk Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- SPARCIndependent statistical analysis of Sustaining Patient-centered Alcohol-related Care: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02675777).
- SPARKIndependent statistical analysis of Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- SPARKIndependent statistical analysis of Kuvan® in Phenylketonuria Patients Less Than 4 Years Old: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01376908).
- SPARK2Independent statistical analysis of Phase 2B Study Assessing Pain Relief After Replacement of the Knee: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- SPARKLEIndependent statistical analysis of Safety and Diagnostic Efficacy of Mangoral in Participants With Focal Liver Lesions and Reduced Kidney Function: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…